Sirolimus plus prednisone for the treatment of Erdheim-Chester Disease: a pilot study
Phase 2
Active, not recruiting
- Conditions
- Erdheim-Chester diseaseInflammatory and Immune System - Other inflammatory or immune system disorders
- Registration Number
- ACTRN12613001321730
- Lead Sponsor
- niversity of Parma, Department of Clinical and Experiment Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Diagnosis of Erdheim-Chester with systemic involvement
- Active disease (newly diagnosed progressive disease in patients undergoing other treatments)
Exclusion Criteria
- Concurrent active malignancies or serious infections
- Hypersensitivity to sirolimus and/or prednisone and/or contraindications to their use (uncontrolled diabetes
mellitus, severe osteoporosis with previous fractures)
- Proteinuria > 1g/24h
- Recent major surgery and/or post-surgical complications
- Pregnancy
- Patients partecipating in other trials
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method